PL373570A1 - Doustna zawiesina o przyjemnym smaku i sposób jejwytwarzania - Google Patents

Doustna zawiesina o przyjemnym smaku i sposób jejwytwarzania

Info

Publication number
PL373570A1
PL373570A1 PL03373570A PL37357003A PL373570A1 PL 373570 A1 PL373570 A1 PL 373570A1 PL 03373570 A PL03373570 A PL 03373570A PL 37357003 A PL37357003 A PL 37357003A PL 373570 A1 PL373570 A1 PL 373570A1
Authority
PL
Poland
Prior art keywords
oral suspension
palatable oral
palatable
suspension
oral
Prior art date
Application number
PL03373570A
Other languages
English (en)
Other versions
PL212421B1 (pl
Inventor
Ismat Ullah
Gary J. Wiley
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL373570A1 publication Critical patent/PL373570A1/pl
Publication of PL212421B1 publication Critical patent/PL212421B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL373570A 2002-03-12 2003-03-06 Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku PL212421B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36370402P 2002-03-12 2002-03-12

Publications (2)

Publication Number Publication Date
PL373570A1 true PL373570A1 (pl) 2005-09-05
PL212421B1 PL212421B1 (pl) 2012-09-28

Family

ID=28041802

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373570A PL212421B1 (pl) 2002-03-12 2003-03-06 Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku

Country Status (16)

Country Link
US (1) US7175856B2 (pl)
EP (1) EP1482789A4 (pl)
JP (1) JP4619658B2 (pl)
CN (1) CN100337630C (pl)
AR (1) AR038947A1 (pl)
AU (1) AU2003220058B2 (pl)
BR (1) BR0308343A (pl)
CA (1) CA2478411C (pl)
MX (1) MXPA04008720A (pl)
NO (1) NO20043986L (pl)
NZ (1) NZ534746A (pl)
PE (1) PE20030885A1 (pl)
PL (1) PL212421B1 (pl)
TW (1) TW200304832A (pl)
WO (1) WO2003077842A2 (pl)
ZA (1) ZA200406585B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4705108B2 (ja) * 2004-10-15 2011-06-22 ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト 改良されたパンコーティング法
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
CA2681545C (en) 2007-03-28 2013-10-01 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
CA2721134C (en) * 2007-06-13 2017-02-07 Wayne State University Board Of Governors A baclofen solution for low-volume therapeutic delivery
WO2008157308A2 (en) * 2007-06-13 2008-12-24 Wayne State University Board Of Governors A zwitterion solution for low-volume therapeutic delivery
JP5009707B2 (ja) * 2007-07-10 2012-08-22 東和薬品株式会社 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤
US7884227B2 (en) * 2007-10-26 2011-02-08 Navinta Llc Felbamate with improved bulk density
WO2009092002A1 (en) * 2008-01-17 2009-07-23 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
PL2268282T3 (pl) * 2008-04-25 2015-04-30 Apotex Tech Inc Płynny preparat deferypronu o przyjemnym smaku
ES2351643B1 (es) * 2009-07-27 2011-09-15 Laboratorio Jaer,S.A. Utilización de xilitol o sus derivados para el enmascaramiento gustativo de quimioterápicos del grupo del ácido quinolon-o-naftiridoncarboxílico administrados en alimentos destinados a ganado porcino.
WO2010034853A1 (es) 2008-09-23 2010-04-01 Laboratorio Jaer, S.A. Utilización de exilitol o sus derivados para el enmascaramiento gustativo de quimioterapicos del grupo del ácido quinolon-o-naftiridoncarboxilico administrados en alimentos destinados a ganado porcino
ES2335334B1 (es) * 2008-09-23 2011-02-09 Laboratorio Jaer, S.A. Utilizacion del xilitol para el enmascaramiento gustativo de amargantes en alimentos para animales.
ME01911B (me) 2009-07-03 2014-12-20 Apotex Tech Inc Fluorisani derivati 3-hidroksipiridin-4-ona
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
US20110236494A1 (en) * 2010-03-04 2011-09-29 Ranbaxy Laboratories Limited Ciprofloxacin oral suspension
GB201006218D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
CN102397546A (zh) * 2010-09-10 2012-04-04 广州自远生物科技有限公司 一种用于嗅觉或味觉敏感型动物的药物给药方法
CN102397552B (zh) * 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN111201013A (zh) * 2017-10-13 2020-05-26 研究三角协会 硫酸羟基氯喹制剂及其制备和使用方法
CN110151704A (zh) * 2019-07-05 2019-08-23 华裕(无锡)制药有限公司 阿奇霉素干混悬剂的制备方法
WO2025043236A1 (en) * 2023-08-24 2025-02-27 Joseph Fuisz Edible oral films, compositions, method of manufacture and packaging systems

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
JPS61180771A (ja) * 1985-01-05 1986-08-13 バイエル・アクチエンゲゼルシヤフト 安定な抗バクテリア剤水溶液
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
DE3831514A1 (de) * 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
US5262179A (en) * 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
JP3184239B2 (ja) * 1991-04-25 2001-07-09 京都薬品工業株式会社 矯味経口用医薬組成物
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JPH05309314A (ja) 1992-05-07 1993-11-22 Sumitomo Pharmaceut Co Ltd コーティング方法
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
ATE245638T1 (de) * 1994-08-12 2003-08-15 Toyama Chemical Co Ltd Neue chinolon- oder naphthyridoncarbonsäurederivate oder deren salze
JPH10511640A (ja) * 1994-10-14 1998-11-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ サベルゾール経口懸濁剤
US5738875A (en) * 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
DK0801559T3 (da) * 1995-02-08 2002-06-17 Yamanouchi Europ Bv Fremgangsmåde til fremstilling af orale doseringsformer indeholdende et beta-lactam antibiotikum
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
WO1997029102A1 (en) * 1996-02-09 1997-08-14 Toyama Chemical Co., Ltd. Quinolonecarboxylic acid derivatives or salts thereof
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
JP3424038B2 (ja) * 1996-06-17 2003-07-07 株式会社日本点眼薬研究所 合成抗菌剤水性組成物
PL196867B1 (pl) * 1999-05-27 2008-02-29 Pfizer Prod Inc Kompozycja zyprazydonu
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions

Also Published As

Publication number Publication date
NZ534746A (en) 2006-06-30
MXPA04008720A (es) 2004-12-06
US20030187019A1 (en) 2003-10-02
AR038947A1 (es) 2005-02-02
WO2003077842A3 (en) 2004-03-25
TW200304832A (en) 2003-10-16
CN1642415A (zh) 2005-07-20
US7175856B2 (en) 2007-02-13
PL212421B1 (pl) 2012-09-28
JP2006504620A (ja) 2006-02-09
WO2003077842A2 (en) 2003-09-25
CA2478411C (en) 2010-09-28
JP4619658B2 (ja) 2011-01-26
AU2003220058B2 (en) 2008-05-01
CN100337630C (zh) 2007-09-19
CA2478411A1 (en) 2003-09-25
BR0308343A (pt) 2006-06-06
AU2003220058A1 (en) 2003-09-29
NO20043986L (no) 2004-09-23
PE20030885A1 (es) 2003-10-23
ZA200406585B (en) 2005-11-30
EP1482789A2 (en) 2004-12-08
EP1482789A4 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
IL165333A0 (en) Probiotics and oral tolerance
IL164703A0 (en) ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
AU2003286874A8 (en) Parameterizing system and method
EP1575495A4 (en) COMPOUNDS AND METHODS
AU2003256904A8 (en) Plurality of bags and method of making the same
NO20043986L (no) Velsmakende oral suspensjon og framgangsmate for fremstilling av suspensjonen.
AU2003269444A8 (en) An improved pacifier and method of use thereof
EP1355501A4 (en) SEPARATE LEVEL FOR Y / C SIGNALS AND ITS PROCEDURE
GB2395642B (en) Arbitration unit and method
AU2002351206A1 (en) Lateral lubistor structure and method
GB2390439B (en) Dataconferencing system and method
AU2002257312A8 (en) Offer system and method
AP2005003317A0 (en) Product and method
AU2003265366A8 (en) Recharging method and apparatus
AU2003296159A8 (en) Multiple particles and method for preparation thereof
GB0215867D0 (en) Novel method and compounds
GB2394021B (en) Connection method and assembly
EP1499338A4 (en) 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES
GB0206339D0 (en) Monitoring software and method
AU2003223357A8 (en) Compounds and methods
EP1617774A4 (en) SYSTEM AND METHOD FOR ORAL TREATMENTS
GB0203295D0 (en) Novel method and compounds
GB0209474D0 (en) Method and means of wing-rotor transition
GB2405299B (en) Arbitration unit and method
GB0202774D0 (en) Methods and means